Subtype
Low Grade Glioma
CI-CAN-00003062LGGExplore in graph →
Non-malignant115 active trials62 evidence items
- NCIt
- C132067
- OncoTree
- LGGNOS
- DOID
- 0080829
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00003062LGGExplore in graph →
Clinical trials
324 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03969706 | Abemaciclib in Patients With Oligodendroglioma | completed | Phase 2 | 10 | Stephen Bagley, MD, MSCEOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03251989 |
| Rare CNS Tumors Outcomes &Risk |
| completed |
| — |
| 326 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT02455245 | A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma | completed | Phase 3 | 95 | Alicia LenzenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03900689 | Social Determinants of Health in Glioblastoma Population | completed | — | 100 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07673666 | GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)(GliomaAI-A23) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673705 | GliomaAI-Oligo: MRI-Based Detection of IDH Mutant Oligodendroglioma(GliomaAI-Oligo) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT01096368 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | completed | Phase 3 | 479 | Children's Oncology GroupNETWORK | 4 | Apr 30, 2026 | clinicaltrials |
| NCT06625047 | Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy | completed | Phase 4 | 30 | Mayo ClinicOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT05393258 | Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas | completed | N/A | 13 | Washington University School of MedicineOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04044937 | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms(UC-GlioFET) | completed | Phase 2 | 143 | Thomas HopeOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03429803 | DAY101 In Gliomas and Other Tumors | completed | Phase 1 | 44 | Karen D. Wright, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02473380 | Fluorescence Spectroscopy Guided Surgery(GLIOSPECT) | completed | Phase 1 | 11 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02238899 | Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma | completed | — | 354 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT01295944 | Carboplatin and Bevacizumab for Recurrent Ependymoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03128047 | HUMC 1612: Optune NovoTTF-200A System | completed | Phase 1 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT04734444 | SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue | completed | N/A | 45 | SonoClear ASINDUSTRY | 3 | Jun 17, 2025 | clinicaltrials |
| NCT01288235 | Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation | completed | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03572530 | Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma(5-AZA) | completed | Phase 1 | 3 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT01553149 | Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 4 | Jan 7, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT01130077 | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas | completed | Phase 1 | 60 | James FelkerOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02530320 | Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | completed | Phase 2 | 34 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02549833 | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | completed | Phase 1 | 28 | Jennie TaylorOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04304300 | Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes(RIGEL) | completed | — | 80 | Erasmus Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02155920 | Everolimus for Children With Recurrent or Progressive Ependymoma | completed | Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03206021 | COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors(COZMOS) | completed | Phase 1 | 31 | The Hospital for Sick ChildrenOTHER | 3 | Apr 5, 2024 | clinicaltrials |
| NCT04408092 | Study of the Effect of GM-CSF on Macrophages in Ependymoma | completed | Early Phase 1 | 6 | University of Colorado, DenverOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05873946 | Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery(2D-ioUS-Glio) | completed | — | 99 | Hospital del Rio HortegaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | completed | Phase 1 | 8 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04659421 | Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas | completed | Phase 2 | 60 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04708548 | Long Term Implications of Rare Brain Tumours' | completed | — | 267 | Galina VelikovaOTHER | 2 | May 15, 2023 | clinicaltrials |
| NCT03860376 | Ex Vivo Drug Sensitivity Testing and Mutation Profiling | completed | — | 25 | Florida International UniversityOTHER | 1 | May 10, 2023 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials